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measures from the Clinical Global Impression scale. Ad-
ditional variables include relevant demographic and dis-
ease characteristics.
RESULTS: Depressed patients treated with reboxetine
have a greater increase in SASS score from baseline rela-
tive to those treated with fluoxetine. We found that this
increased effect of reboxetine depends on both the pa-
tient’s clinical severity and measurement time. We also
found a significant association between the percentage
change from baseline HAM-D score and the percentage
change from baseline SASS score.
CONCLUSIONS: Our results suggest that, after control-
ling for patient characteristics and measures of depres-
sion severity, reboxetine is more effective than fluoxetine
at increasing overall social functioning as measured by
the SASS.
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OBJECTIVE: The purpose of this study was to evaluate,
from the perspective of California’s Medicaid program
(Medi-Cal), the policy decision to include fluoxetine on
its formulary. The analysis includes a review of the for-
mulary adoption process, financial inducement, and data
presented to the Medi-Cal program.
METHODS: The time horizon for this analysis extends
from 1996 to 2004 (the date of formulary inclusion until
patent expiration). Using 1994–1997 values as a base-
line, calculation of the incremental Net Present Value in-
volved projecting fluoxetine’s acquisition price, phar-
macy dispensing fee, manufacturer’s rebate, treatment
authorization costs, CPI for prescription drugs and medi-
cal care, number of eligibles enrolled in Medi-Cal fee-for-
service, fee-for-service eligibles to be transferred into
managed care, population projections, and cost of inten-
tion to treat with fluoxetine (which included treatment
failures). The net savings in cost-of-care per patient of
$3524 (1994 US dollars, p  0.0024) was provided by
previous research. The annual discount rate employed
was 5.707%, the FY 1996–1997 rate for the Pooled
Money Investment Account (the state’s general funding
for Medi-Cal).
RESULTS: The model yielded a Net Present Value for flu-
oxetine formulary inclusion, which resulted in estimated
savings to the State of between $1.025 and $1.760 billion
over the 8-year time frame. The sensitivity analysis in-
volved varying the projected number of fee-for-service eli-
gibles to be transferred into contracted managed care.
CONCLUSION: The potential savings to be derived from
the appropriate treatment of persons suffering from major
depressive disorder are socially and economically signifi-
cant. More emphasis should be placed on the appropriate
pharmacotherapy of major depressive disorder, since the
drug acquisition costs are minimal in comparison to the
associated healthcare and indirect societal costs.
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Diabetes is a common risk factor for cardiovascular dis-
ease. Depression is associated with cardiovascular disease
and may negatively impact overall management.
OBJECTIVE: The objective of this study was to docu-
ment the presence of cardiovascular risk factors (diabetes
mellitus, hypertension, and hyperlipidemia) and the phar-
macotherapeutic management of these conditions in pri-
mary care patients receiving antidepressant medications.
METHODS: The electronic medical records (EMR) of
primary care patients at an academic medical center were
evaluated for the above clinical conditions and medica-
tions. Only patients prescribed an antidepressant drug
within the previous 6 months were reviewed, in the order
in which they were entered into the EMR system.
RESULTS: The electronic records of 115 patients receiv-
ing antidepressant drugs were reviewed by two physician
researchers. Data for 88 (76.5%) female and 27 (23.5%)
male patients were evaluated. The mean age for these pa-
tients was 46.5 years. Sixty-one (53.0%) patients were
white, 38 (33.0%) were black. Twenty-one (18.3%) pa-
tients had diabetes, 56 (48.7%) had hypertension, and 14
(12.2%) had hyperlipidemia. Of special significance was
that 20 of 21 (95.2%) patients with diabetes also had hy-
pertension. In addition to cardiovascular risks, 13 (11.2%)
had developed coronary artery disease with an additional
3 (2.6%) patients having had myocardial infarction. The
mean number of prescriptions for 58 patients without dia-
betes and hypertension was 2.1 while the mean for 20 pa-
tients with diabetes and hypertension was 7.0.
CONCLUSIONS: The link between cardiovascular risk
and antidepressant drug use seems to be strong. Clini-
cians should emphasize the management of cardiovascu-
lar risk factors in these patients.
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